参芪扶正注射液联合CHOP方案治疗恶性淋巴瘤的临床研究

作者	单位
王文玲	贵阳医学院附属医院肿瘤科贵阳550004
文小平	贵阳医学院附属医院肿瘤科贵阳550004
韩蕾	贵阳医学院附属医院肿瘤科贵阳550004
马莉	贵阳医学院附属医院肿瘤科贵阳550004

摘要点击次数: 1343

全文下载次数: 1

中文摘要:

目的比较参芪扶正注射液联合CHOP方案或单纯CHOP方案治疗中度非霍奇金氏恶性淋巴瘤的疗效及不良反应。方法入选的60例中度非霍奇金氏恶性淋巴瘤患者分为两组,观察组32例,采用参芪扶正注射液联合CHOP方案治疗,平均化疗5．7周期。对照组28例,单纯用CHOP方案治疗,平均化疗5．6周期。结果观察组完全缓解(CR)18例,部分缓解(PR)4例,稳定(NC)7例,进展(PD)3例,总有效率为68．8％;对照组CR 13例,PR 4例,NC 7例,PD 4例,总有效率为60．7％。观察组治疗后与对照组比较CD3、CD4、CD4／CD8比值明显升高,CD8明显下降,差异有显著性(P<0．05)。观察组白细胞降低、神经毒性及心脏毒性的发生率明显低于对照组(P<0．01)。观察组生活质量改善较对照组明显(P<0．05)。结论参芪扶正注射液联合CHOP方案治疗中度恶性淋巴瘤可起到减轻化疗的不良反应,使患者化疗依从性更好,增强机体的免疫功能,改善患者生活质量的作用。

英文摘要:

Objective To compare the efficacy and adverse reaction of chemotherapy in CHOP protocol (CT-CHOP) alone or compared with Shenqi Fuzheng injection (SFI) for treatment of moderate malignant non-Hodgkin’s lymphoma. Methods Sixty patients were divided into 2 groups, the treated group(n=32) treated with CT-CHOP plus SFI for 5.7 cycles on average and the control group(n=28) treated with CT-CHOP alone for 5.6 cycles on average. Results In the treated group, 18 patients were completely remitted (CR), 4 were partially remitted (PR), 7 were unchanged (NC), 3 were progressively deteriorated (PD), with the total remission rate of 68.8% , while in the control group, 13 were CR, 4 PR, 7 NC and 4 PD, the total remission rate being 60.7% . After treatment, the levels of CD3, CD4 and CD4/CD8 increased and CD8 decreased significantly in the treated group (P<0.05). Patients’ quality of life (QOL) in the treated group was improved more obviously than that in the control group (P<0.01), and the incidence rate of adverse reaction as leucopenia, neurotoxicity, and cardiac toxicity were lower in the treated group than those in the control group (P<0.01). Conclusion Shenqi Fuzheng injection combined with CT-CHOP on malignant non-Hodgkin’s lymphoma can reduce the adverse reaction of chemotherapy, ameliorate the compliance of patients to chemotherapy, and improve the immune function and QOL of patients.

关闭